Pfizer Builds Upon Robust Body Of Knowledge For XELJANZA With Clinical Trial And Real-World Use Data At The European League Against Rheumatism Annual Congress )--Pfizer Inc. announced today that more than 20 abstracts including new rheumatoid arthritis research for XELJANZA will be presented at the European League Against Rheumatism Annual Congress June 10-15, Rome, Italy. Highlights include over six-years of safety and efficacy data from two long-term extension studies, real-world experience analyses, and clinical, patient-reported and radiographic efficacy outcomes with XELJANZ monotherapy, as well as health economics outcomes research that include patient-preference data for XELJANZ in patients with RA.
↧